Meridian Bioscience (VIVO) Reports Q4 EPS of $0.19, Offers FY21 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Meridian Bioscience Reports Strong Fourth Quarter and Record Full-Year Fiscal 2020 Operating Results and Provides Fiscal 2021 Guidance
November 13, 2020 7:30 AM ESTCINCINNATI, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2020.
Fourth Quarter 2020 Highlights (Comparison to Fourth Quarter Fiscal 2019):
Consolidated Net Revenue of $64.2 million, up 26% year-over-yearLife Science segment delivers revenue of $34.4 million, up 97% year-over-yearDiagnostics segment revenues decreased 11% year-over-year to $29.8 million, a stronger than expected rebound from Q3 FY20, up 38% quarter-over-quarterLaunched various SARS-CoV-2 antibody pairs, designed for highly sensitive rapid antigen tests (for saliva and... More